

Siegfried opens new quality control lab in Minden

Media Release

Zofingen

August 30, 2024

Siegfried inaugurated its new state-of-the-art quality control lab in Minden. The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant.

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), inaugurated its new state-of-the-art lab in Minden, Germany. The new facility hosts workstations for more than 60 employees and high precision equipment across an area of more than 600 square meters. The new lab combines several quality control units in one location, creating synergies and efficiencies as well as increasing the overall quality control capacity across the site.

The facility will provide the additional quality control capacities needed upon the completion of the new large-scale production plant, which is currently under construction. The new production facility will host approximately 100 cubic meters additional reactor capacity and will significantly increase the capacity for Siegfried's Drug Substance activities, expanding the technological capabilities and the flexibility of Siegfried's global network.

Reto Suter, Chief Executive Officer ad interim and Chief Financial Officer: "The new lab facility further strengthens our manufacturing site in Minden and highlights our commitment to offer the most advanced quality control services to our customers, ensuring the safety of the products we produce for millions of patients worldwide. It further underpins our commitment to operate a world class drug substances manufacturing network."

With the opening of the new lab and the plant under construction, Siegfried further strengthens its footprint in Germany, where it has two sites in Minden and Hameln. At its two German sites, Siegfried manufactures a wide range of Active Pharmaceutical Ingredients (APIs), as well as finished drug products like vials and ampoules.

Contact Media

Peter Stierli
Head Corporate Communications
peter.stierli@siegfried.ch
+41 62 746 15 51

Contact Financial Analysts

Dr. Reto Suter
CEO ad interim and Chief Financial Officer
reto.suter@siegfried.ch
+41 62 746 11 35

Siegfried Holding AG,
Untere Bruehlstrasse 4
CH-4800 Zofingen

www.siegfried.ch

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3'700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.